Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | F2R | P25116 | 1/20 | 0.39 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7089251 | 0.84 | SMN1; SMN2 (0.44) | KDM4EL3MBTL1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL4062908 | 0.81 | L3MBTL1 (0.54) | KDM4EL3MBTL1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL662972 | 0.81 | KDM4E (0.61) | KDM4EL3MBTL1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL15007 | 0.81 | KDM4E (0.61) | KDM4EL3MBTL1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL10329925 | 0.80 | L3MBTL1 (0.40) | KDM4EL3MBTL1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL23763990 | 0.79 | RRM2 (0.49) | KDM4EL3MBTL1ALDH1A1KCNJ1HRH3 | |
| SCHEMBL3903323 | 0.79 | KCNJ1 (0.39) | KDM4EL3MBTL1ALDH1A1MAPTKCNJ1 | |
| SCHEMBL951851 | 0.79 | KDM4E (0.59) | KDM4EL3MBTL1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL6245688 | 0.79 | KDM4E (0.42) | KDM4EL3MBTL1NPC1RAB9AALDH1A1 | |
| SCHEMBL31261054 | 0.79 | KDM4E (0.59) | KDM4EL3MBTL1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025064325-A1 | GPR35 MODULATORS | PROMETHEUS BIOSCIENCES, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20150299143-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-10-22 | — | — | US | disclosed |
| EP-2925746-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2015-10-07 | — | — | EP | disclosed |
| CN-104968657-A | Substituted triazole and imidazole compounds | HOFFMANN LA ROCHE | 2015-10-07 | — | — | CN | disclosed |
| US-8993773-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2015-03-31 | — | — | US | disclosed |
| WO-2014086663-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | disclosed |
| EP-2022793-B1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2014-06-04 | — | — | EP | disclosed |
| US-20140088127-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | CADILA HEALTHCARE LIMITED (IN) | 2014-03-27 | — | — | US | disclosed |
| EP-1724263-B1 | BASIC AMINE COMPOUND AND USE THEREOF | KUREHA CORP (JP) | 2014-03-05 | — | — | EP | disclosed |
| CN-1379777-A | Amino-triazolopyridine derivatives | HOFFMANN LA ROCHE (CH) | 2002-11-13 | — | — | CN | disclosed |
| EP-1214322-A2 | AMINO-TRIAZOLOPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-19 | — | — | EP | disclosed |
| US-6355653-B1 | DRUG AND CARRIER FOR ANTIALLERGENS, BRAIN DISORDERS AND NEUROTRANSMITTERS | HOFFMANN-LA ROCHE INC. | 2002-03-12 | — | — | US | disclosed |
| WO-2001017999-A2 | AMINO-TRIAZOLOPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-03-15 | — | — | WO | disclosed |
| EP-0313630-B1 | SUBSTITUTED 2-ACYLPYRIDIN-ALPHA-(N)-HETARYLHYDRAZONES AND MEDICAMENTS CONTAINING SAME | DEUTSCHES AUSSÄTZIGEN HILFSWERK E.V. (DE) | 1992-09-16 | — | — | EP | disclosed |
| US-5084458-A | Bactericides, malaria and antitumor agents | SCHAPER KLAUS JUERGEN (DE) | 1992-01-28 | — | — | US | disclosed |
| US-4997835-A | Bactericides, malaria, antitumor | SCHAPER KLAUS JUERGEN (DE) | 1991-03-05 | — | — | US | disclosed |
| EP-0313630-A1 | SUBSTITUTED 2-ACYLPYRIDIN-ALPHA-(N)-HETARYLHYDRAZONES AND MEDICAMENTS CONTAINING SAME. | DEUTSCHES AUSSATZIGEN HILFSWER (DE) | 1989-05-03 | — | — | EP | disclosed |
| CN-85103724-A | The method for preparing novel pyrrolo-benzoglyoxaline | — | 1986-07-02 | — | — | CN | disclosed |
| US-3937701-A | 1-(10-Cyano/halo-5H-dibenzo[a,d]cyclohepten-5-yl)-4-[(pyridylmethylene)amino]piperazines | G. D. SEARLE & CO. (US) | 1976-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299143-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | HDAC7, PSMB7, IKZF3 | KDM4E 865/4885L3MBTL1 3540/4885SMN1; SMN2 4492/4885 |
| US-20140088127-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | PPARD, PPARG, PPARA | KDM4E 3954/4885L3MBTL1 4864/4885SMN1; SMN2 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.